Bicara Therapeutics Management
Management criteria checks 1/4
Bicara Therapeutics' CEO is Claire Mazumdar Clemon, appointed in Jan 2020, has a tenure of 5.08 years. total yearly compensation is $4.54M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $2.60M. The average tenure of the management team and the board of directors is 2.1 years and 1.7 years respectively.
Key information
Claire Mazumdar Clemon
Chief executive officer
US$4.5m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.1yrs |
| Board average tenure | 1.7yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$59m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$450k | -US$52m |
Compensation vs Market: Claire's total compensation ($USD4.54M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Insufficient data to compare Claire's compensation with company performance.
CEO
Claire Mazumdar Clemon (35 yo)
5.1yrs
Tenure
US$4,543,323
Compensation
Ms. Claire Mazumdar Clemon, PhD, M.B.A., serves as Chief Executive Officer and Director of Bicara Therapeutics Inc since January 2020 and served as its President. She served as Senior Associate at Third Ro...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.1yrs | US$4.54m | 0.39% $ 2.6m | |
| President | 4.3yrs | US$3.16m | 0.20% $ 1.4m | |
| Chief Financial Officer | 3.9yrs | US$2.48m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 1.3yrs | no data | no data | |
| SVP of R&D Strategy and Operations | no data | no data | no data | |
| Senior VP and Head of Technical Operations & Supply Chain | 2.1yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | 0.065% $ 436.6k | |
| VP & Head of Regulatory Affairs | 2.1yrs | no data | no data | |
| Senior Vice President of Clinical & Medical Affairs | less than a year | no data | no data | |
| Senior VP & Global Head of Quality Assurance | no data | no data | no data | |
| VP of Finance & Controller | no data | no data | no data |
2.1yrs
Average Tenure
48yo
Average Age
Experienced Management: BCAX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.1yrs | US$4.54m | 0.39% $ 2.6m | |
| President | no data | US$3.16m | 0.20% $ 1.4m | |
| Independent Chairman of the Board | less than a year | no data | no data | |
| Non-Executive Independent Director | 5.8yrs | US$150.66k | 0.031% $ 205.0k | |
| Board Observer | no data | no data | no data | |
| Independent Director | 6.2yrs | no data | 0.83% $ 5.5m | |
| Independent Director | 1.4yrs | US$175.90k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Independent Director | 1.4yrs | US$175.90k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Non-Executive Independent Director | 1.2yrs | no data | no data | |
| Non Executive Independent Director | 1.9yrs | no data | no data |
1.7yrs
Average Tenure
48yo
Average Age
Experienced Board: BCAX's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 00:26 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bicara Therapeutics Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Richard Law | Goldman Sachs |
| Robert Burns | H.C. Wainwright & Co. |